OTC:VYCO
VYCOR MEDICAL INC
Vycor Medical Inc. (VYCO) is an OTC-traded developer of innovative medical devices aimed at streamlining clinical workflows and enhancing patient safety in surgical environments.
Key Metrics
Investment Thesis
Bull Case
Vycor Medical offers exposure to the growing medical device sector with a potential turnaround story if the company can achieve operational leverage through its current revenue expansion. Investors may view the negative net income as an investment phase, noting that cash flow from operations remains positive at $60k while capital expenditures are contained at roughly $4k. The specialized nature of its product line suggests strong retention rates once installed in facilities, potentially unlocking future value upon achieving profitability.
Bear Case
The substantial accumulated deficit of $33.3 million and negative shareholders' equity of $3.7 million signal deep structural financial weaknesses that could lead to insolvency or dilution via new equity issuances. Persistent operating losses combined with high administrative costs suggest management inefficiencies that have not improved despite revenue growth, raising doubts about the viability of current business models. With total liabilities significantly outpacing assets, the company lacks a robust balance sheet to weather economic downturns or invest in necessary technological upgrades.
About VYCOR MEDICAL INC
Vycor Medical Inc. specializes in developing advanced medical devices and technologies designed to enhance patient care across various clinical settings. The company serves hospitals, surgical centers, and outpatient facilities with innovative solutions focused on improving operational efficiency and procedural outcomes. Key product offerings include specialized instrumentation and integrated systems that address critical needs in modern healthcare delivery.
Analysis
Management Discussion
Despite achieving a modest 32% year-over-year revenue growth to $1.6 million in 2024, the company continues to report significant operating losses driven by high general and administrative expenses of $1.4 million. Cash flow from operations of $60,110 partially offsets financing outflows, yet the accumulated deficit suggests management has struggled to translate revenue into sustainable earnings over the past three years. The increase in accounts receivable and inventory levels indicates scaling efforts that have not yet resulted in proportional cost reductions.
Industry Overview
The global medical device market is experiencing steady expansion driven by aging populations and increased demand for minimally invasive surgical procedures that require specialized instrumentation. Competition remains fierce among established multinational corporations and innovative startups, creating a challenging environment for smaller players lacking significant R&D budgets. Regulatory compliance costs continue to rise as governments worldwide implement stricter oversight on manufacturing standards and post-market surveillance requirements.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $1.2M | $1.5M | $1.6M |
| Cost of Revenue | $140.6K | $144.9K | $166.8K |
| Gross Profit | $1.1M | $1.3M | $1.4M |
| Operating Expenses | $1.4M | $1.3M | $1.4M |
| Operating Income | $-306.5K | $40.2K | $-9.1K |
| R&D | — | $22.6K | $15.3K |
| G&A | $1.3M | $1.2M | $1.4M |
| Stock-Based Comp | $185.6K | $10.1K | $26.8K |
| D&A | $58.2K | $57.5K | $59.5K |
| Depreciation | $61.4K | $60.8K | $63.9K |
| Other OpEx | $58.2K | $57.5K | $59.5K |
| Non-Operating Income | $-93.2K | $-103.3K | $-97.8K |
| Pre-Tax Income | $-399.7K | $-63.1K | $-107.0K |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-399.7K | $-63.1K | $-107.0K |
| Discontinued Ops | $-5.2K | $-6.6K | $-249 |
| Net Income | $-404.9K | $-69.7K | $-107.2K |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-404.9K | $-69.7K | $-107.2K |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $517.8K | $584.1K | $695.7K |
| Cash & Equivalents | $37.0K | $57.3K | $105.6K |
| Accounts Receivable | $156.2K | $215.2K | $245.3K |
| Inventory | $248.9K | $234.1K | $222.2K |
| Prepaid Expenses | $74.4K | $76.7K | $121.7K |
| Other Current Assets | $1.2K | $739 | $917 |
| Long-Term Assets | $342.4K | $408.2K | $302.4K |
| PP&E (Net) | $303.8K | $252.4K | $192.7K |
| Operating Leases | $32.6K | $149.8K | $103.7K |
| Other LT Assets | $6.0K | $6.0K | $6.0K |
| Total Assets | $860.2K | $992.3K | $998.1K |
| Current Liabilities | $3.7M | $4.1M | $4.5M |
| Accounts Payable | $200.0K | $117.8K | $147.6K |
| Current Leases | $29.6K | $45.3K | $48.2K |
| Other Current Liab | $3.4M | $3.9M | $4.3M |
| Long-Term Liabilities | $146.3K | $243.3K | $191.7K |
| LT Operating Leases | — | $100.4K | $52.2K |
| Other LT Liab | — | $142.9K | $139.4K |
| Total Liabilities | $3.8M | $4.3M | $4.7M |
| Shareholders' Equity | $-2.9M | $-3.3M | $-3.7M |
| Paid-In Capital | $29.4M | $29.4M | $29.4M |
| Retained Earnings | $-32.4M | $-32.8M | $-33.3M |
| AOCI | $127.7K | $127.7K | $127.7K |
| Treasury Stock | $1.0K | $1.0K | $1.0K |
| Total L&E | $860.2K | $992.3K | $998.1K |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-404.9K | $-69.7K | $-107.2K |
| Non-Cash Adjustments | $57.0K | $-24.9K | $8.2K |
| Working Capital Changes | $130.9K | $124.0K | $159.2K |
| Cash from Operations | $-217.0K | $29.4K | $60.1K |
| Capital Expenditures | $2.8K | $9.4K | $4.2K |
| Cash from Investing | $-2.8K | $-9.4K | $-4.2K |
| Cash from Financing | $165.9K | $211 | $-7.6K |
| FX Effect | $1 | $1 | $0 |
| Net Change in Cash | $-53.9K | $20.3K | $48.4K |
| Beginning Cash | $90.9K | $37.0K | $57.3K |
| Ending Cash | $37.0K | $57.3K | $105.6K |
Frequently Asked Questions
How does VYCOR MEDICAL INC make money?
The company's revenue streams primarily consist of sales of proprietary medical instrumentation, distribution of specialized healthcare technologies, and licensing of intellectual property related to device innovation. Additional segments include service contracts for equipment maintenance and support, as well as strategic partnerships with established healthcare institutions for pilot testing and deployment of new technologies.
What are the main risks for VYCO?
Significant negative net income of $107,200 and a substantial retained earnings deficit of $33.3 million indicate ongoing profitability challenges that threaten long-term sustainability. The company faces liquidity constraints with total liabilities exceeding assets by approximately $4 million, limiting financial flexibility for expansion or R&D investments. Reliance on a limited number of large hospital clients creates concentration risk, where loss of a single major contract could materially impact revenue stability. Regulatory hurdles and stringent FDA approval processes for new medical devices present substantial time-to-market risks that could delay product launches.
What is VYCO's competitive advantage?
Vycor Medical leverages a niche portfolio of patented medical devices that offer unique functionalities difficult to replicate by larger competitors, creating a high barrier to entry. The company maintains strong relationships with key surgical centers through early adoption programs, ensuring steady demand cycles for its specialized equipment. Operational agility allows Vycor to rapidly adapt product offerings to emerging clinical trends without the bureaucratic overhead of public sector giants.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.